Imagine a fast-acting blood test that works like a digital fingerprint scanner for medicine. Instead of sending samples to a distant lab and waiting hours, doctors can check antibiotic levels right at the bedside in 15 minutes. This helps them adjust doses instantly to save lives and prevent drug resistance.
Current antibiotic monitoring in ICUs is too slow and expensive, leading to inappropriate dosing for 50% of sepsis patients. This results in higher mortality, toxicity, and increased antibiotic resistance.
An automated PoC device featuring a centrifugal microfluidics cartridge and a label-free SERS chip reader for rapid drug quantification.
If you are an IVD manufacturer dealing with slow lab-based drug monitoring — this project developed a microfluidics cartridge and SERS reader that provides antibiotic concentrations in 15 minutes. This allows for a transition from centralized labs to bedside testing.
If you are a hospital group dealing with high sepsis mortality and inappropriate dosing in 50% of patients — this project developed an automated PoC device that optimizes patient treatments. This reduces adverse events and improves ICU efficiency.
If you are a pharma company dealing with the need for precise drug level quantification during trials — this project developed a label-free SERS sensor platform. This provides a flexible and scalable way to monitor various drug types beyond antibiotics.
Based on available project data, specific pricing is not mentioned, but the system is described as a cost-effective alternative to current slow and expensive workflows.
Yes, the project focuses on enhancing sensor uniformity and preparation to make scaling up production possible.
The project aims to found a spin-off company to commercialize the technology and eventually seek a global distribution deal with a large diagnostics company.
It is designed as a benchtop device with a microfluidics cartridge for seamless integration into ICUs and decentralized healthcare settings.
The project runs from 2024-05-01 to 2027-04-30, with the goal of making the technology investment-ready and generating early revenues via a spin-off.
The consortium is highly concentrated, consisting of a single academic partner (Danmarks Tekniske Universitet) from one country (Denmark). With 0% industry representation currently, the project is driven by university research, though it explicitly aims to transition into a commercial spin-off.
Contact the Technical University of Denmark (DTU) regarding the ACU-SERS spin-off
Contact us to connect with the ACU-SERS team for licensing or investment opportunities.
